SIBN
HealthcareSI-BONE, Inc. · Medical - Devices · $650M
What is SI-BONE, Inc.?
SI-BONE is a medical device company focused on implantable solutions for musculoskeletal disorders of the sacropelvic region. Headquartered in Santa Clara, California, it serves patients in the United States and internationally.
SI-BONE develops and markets minimally invasive surgical implant systems targeting sacroiliac joint dysfunction, adult spinal deformity, and pelvic fractures. The company sells primarily through a direct sales force, supplemented by distributors. Revenue is generated from the adoption of its implant systems by surgeons and healthcare facilities treating sacropelvic conditions.
SI-BONE was incorporated in 2008 and is based in Santa Clara, California.
- iFuse minimally invasive sacroiliac joint implant system
- iFuse-3D titanium implant with 3D-printed porous surface
- iFuse-TORQ threaded implants for pelvic fracture treatment
Is SIBN a Good Stock to Buy?
UQS Score rates SIBN as Below Average overall.
The Growth pillar stands out as a clear bright spot, reflecting meaningful top-line expansion in a niche surgical market. Risk is rated Neutral, suggesting the company does not carry outsized near-term financial or operational hazards relative to peers.
Both the Quality and Moat pillars are rated Weak, pointing to limited competitive differentiation and below-average business fundamentals. Valuation is rated Elevated, meaning the current price may already reflect optimistic growth expectations.
Sign up to see the full pillar breakdown and detailed financial metrics behind SIBN's UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SIBN pay dividends?
No — SI-BONE, Inc. does not currently pay a dividend.
SI-BONE does not currently pay a dividend. As a growth-stage medical device company, capital is directed toward expanding its sales force, funding clinical evidence, and developing next-generation implant technologies rather than returning cash to shareholders.
When does SIBN report earnings?
SI-BONE reports earnings on a quarterly cadence, consistent with US-listed equities.
The company has demonstrated revenue growth driven by broader surgeon adoption of its iFuse product family. Profitability remains a work in progress, as is typical for commercial-stage medical device companies investing heavily in market development.
For the most recent quarter's results, visit SI-BONE's investor relations page directly.
SIBN Price History
-54.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in SI-BONE, Inc.?
Based on SI-BONE, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
SIBN Long-term Outlook
The Growth pillar's Strong rating suggests the underlying demand for minimally invasive sacropelvic solutions continues to expand. However, the Weak Quality and Moat ratings indicate that translating revenue growth into durable profitability remains a challenge. Elevated Valuation adds a layer of risk if growth momentum slows or competition intensifies.
Growth drivers
- Expanding surgeon training and adoption of the iFuse implant family
- Growing clinical evidence supporting sacroiliac joint fusion procedures
- International market expansion beyond the US
Key risks
- Weak competitive moat leaves the company exposed to larger device manufacturers entering the space
- Elevated valuation leaves limited margin of safety if growth disappoints
- Path to consistent profitability remains uncertain given ongoing investment needs
SIBN vs Peers
SI-BONE operates in a niche segment of the medical device market alongside other small-cap healthcare companies.
BrainsWay focuses on non-invasive neuromodulation devices for psychiatric and neurological conditions, a distinctly different therapeutic area from sacropelvic implants.
Cytek Biosciences develops flow cytometry instruments and reagents for life science research, competing in the diagnostics and research tools space rather than surgical implants.
Tactile Systems provides at-home medical devices for chronic conditions like lymphedema, targeting a home-care delivery model rather than the surgical suite.
Frequently Asked Questions
What does SI-BONE do?
SI-BONE develops implantable devices for musculoskeletal disorders of the sacropelvic anatomy. Its core products are minimally invasive implant systems used to treat sacroiliac joint dysfunction, adult spinal deformity, and pelvic fractures. The company sells primarily through a direct sales force in the US and internationally.
Does SIBN pay dividends?
No, SI-BONE does not pay a dividend. The company reinvests available capital into commercial expansion, clinical development, and product innovation rather than distributing cash to shareholders. Dividend-focused investors should factor this into their assessment.
When does SIBN report earnings?
SI-BONE reports on a quarterly cadence, as is standard for US-listed companies. For exact dates and the most recent results, check SI-BONE's investor relations page, as our data source does not provide specific upcoming earnings dates.
Is SIBN a good stock to buy?
UQS Score rates SIBN as Below Average overall. Growth is a genuine strength, but Weak Quality and Moat ratings alongside an Elevated Valuation present meaningful concerns. Investors should weigh those trade-offs carefully. The full pillar breakdown is available to Pro members on UQS Score.
Is SIBN overvalued?
UQS Score's Valuation pillar for SIBN is rated Elevated, suggesting the current market price may already price in considerable growth. This does not guarantee the stock will decline, but it does indicate a reduced margin of safety relative to peers.
How does SIBN compare to its competitors?
SI-BONE occupies a narrow niche in sacropelvic implants, distinct from peers like BrainsWay, Cytek Biosciences, and Tactile Systems, which operate in neuromodulation, research instruments, and home-care devices respectively. Direct product-level competition comes more from larger orthopedic and spine device manufacturers.
What is SIBN's market cap bracket?
SIBN is classified as a small-cap stock. This means it carries characteristics typical of smaller companies — including higher growth potential but also greater volatility and less analyst coverage than large- or mega-cap peers.
Who founded SI-BONE?
SI-BONE was incorporated in 2008. Founding details are publicly available through the company's official disclosures and SEC filings for those seeking the full corporate history.
Is SIBN a long-term quality investment?
From a long-term quality perspective, SIBN's Weak Moat and Weak Quality ratings are cautionary signals. The Strong Growth pillar shows near-term momentum, but durable long-term quality typically requires stronger competitive advantages and more consistent financial fundamentals. Pro members can view the complete analysis.
What is the main competitive advantage of SI-BONE?
SI-BONE's primary differentiation lies in its specialized focus on sacroiliac joint fusion and sacropelvic implants — a niche area with limited direct competition. However, UQS Score rates its Moat as Weak, suggesting this advantage may not yet be deeply entrenched against well-resourced competitors.
Unlock Full SIBN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar scores for SIBN
- ✓Access detailed financial metrics behind the Quality and Growth ratings
- ✓Compare SIBN against sector peers on a standardized scoring framework
- ✓Screen for small-cap healthcare stocks with stronger Moat and Quality ratings
- ✓Get the complete risk and valuation breakdown in one place
Pro Analysis
SIBN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 34.9 | 16.7 | 26.0 | 85.9 | 47.1 | 0.0 | 0.0 |
| Apr 2, 2026 | 34.9 | 16.7 | 26.0 | 85.8 | 47.1 | 0.0 | — |
SIBN — Pillar Breakdown
Quality
— 16.7/100 (25%)SI-BONE, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 85.9/100 (20%)SI-BONE, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 47.1/100 (15%)SI-BONE, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)SI-BONE, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 26/100 (25%)SI-BONE, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SIBN.
Score Composition
Financial Data
More Stock Analysis
How is the SIBN UQS Score Calculated?
The UQS (Unified Quality Score) for SI-BONE, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses SI-BONE, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether SI-BONE, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.